MoCRA K-beauty Import Refusals: Understanding Korea's FDA Labeling Issues

Nothing in an American refusal notice for a Korean cosmetic is about chemistry. In FY2025, 69% of Korea's US FDA cosmetics import refusals came down to labelling, and the same month that Korea's own regulator published its August enforcement record, five of its nine actions were for advertising liable to be mistaken for medicine. The compliance failure that actually stops Korean cosmetics, in both jurisdictions, is the sentence on the label — not the formula in the jar.

Why are Korean cosmetics being refused entry to the United States?

Because of what is written on them.

According to the Korea International Trade Association's Americas office, cited by the Korean trade outlet Cos'In on 24 August 2026, Korea recorded 158 US FDA import refusals for cosmetics in FY2025 — 16.6% of all refusals that year, second by country of origin behind India's 182. (The same report's headline says first; its own KITA figures say second, and the figures are the sourced number.)

FY2024 was 75. The count more than doubled. Refusals had been falling since FY2022 until they turned upward around the point MoCRA became enforceable.

FY2026 does not close until the end of September, and it stood at 171 as of 6 August. The incomplete year has already beaten the complete one.

Sixty-nine per cent of the FY2025 refusals — 109 of 158 — were labelling. Not contamination, not a prohibited ingredient, not a failed microbial specification. Labelling.

69% of Korea's FDA cosmetics refusals in FY2025 came down to labelling, not formulation.

What kind of label wording gets a cosmetic reclassified as a drug?

Language claiming an effect on the structure or function of the body.

Sun protection and acne improvement are among the examples the trade association gives. The FDA's own examples of phrasing that reclassifies a cosmetic as a drug include inhibiting melanin production, stimulating collagen production, hair regrowth and cellulite reduction.

Every one of those sentences is a normal, unremarkable line in a Korean product description.

What did Korea's MFDS actually penalise in August 2026?

The same thing, under a different statute.

On 31 August the Ministry of Food and Drug Safety's August record showed nine administrative actions against seven companies, and five of the nine — the largest single category — were for advertising liable to be mistaken for medicine.

Three companies drew three-month advertising suspensions: Gallery Island for a calamine soap, I FREAK Corp. for a product called Normune 3, and Lelab for a cica cream sold as skin-regenerating. Three more products drew two-month suspensions, including a second Lelab line.

One manufacturer, Cowell Co., Ltd., was found to have written up its quality inspection records arbitrarily and took a corrective order plus a one-month manufacturing suspension on two soap products.

And Sunnyside up took a one-month sales suspension for selling, or storing to sell, a handmade soap shaped like a fried egg — caught under Article 15(10) of the Cosmetics Act, which prohibits cosmetics imitating the form of food. A separate May sweep under the same provision had turned up 95 improper advertisements, 68 of them on cleansing soaps.

Are the Korean and American enforcement problems the same problem?

Read those two records against each other — and this is my reading, not something either source says — and they look like one failure mode in two legal systems.

In Seoul the penalty is a suspension of the right to advertise. In the United States the penalty is a container that does not clear. The defect is a claim written by someone who was not thinking about a claim.

The overlap is not total. Quality-record falsification and food-imitation have no equivalent in the American refusal data. But the largest category on each side is the same category.

MoCRA's first two-year facility registration renewals fall due this year for companies that registered in 2024.

When do MoCRA facility registrations need renewing?

Now, for anyone in the first wave — and this is the version of the problem with a hard date on it.

MoCRA's facility registration and product listing requirements became enforceable on 1 July 2024. Facility registration must be filed within 60 days of beginning manufacture and renewed every two years, which means the first renewals are falling due this year for everyone who registered then.

Product listings must be submitted within 120 days of launch and updated annually, with the responsible person refreshing the full ingredient list in SPL format each year. Miss it and the product is treated as misbranded or adulterated. Nothing changed in the jar; the filing lapsed.

The trade association's advice is worth repeating as given: the FDA does send automatic reminders, and companies should not rely on them — log into Cosmetics Direct and check the status yourself.

Which companies appear in the FDA refusal records?

Manufacturers, mostly — which cuts against the usual story.

Cos'In's own tabulation of FY2026 refusals by company — its research, not the trade association's — puts Seoul Cosmetics at the top with 33, then Cosmax with 23, Cosmecca Korea with 21, GDK Cosmetics with 20 and Nowcos with 14, with Daewoong Pharmaceutical, SJM and Caregen behind them and 41 further companies listed.

The top of that list is contract manufacturers, and one entry is a pharmaceutical company.

Refusal records name the entity on the entry line rather than adjudicating fault, so this is not a finding about who wrote the sentence. It is a finding about where the sentence ends up: attached to a manufacturer's name, in a US federal record, at volume.

Five of the nine MFDS administrative actions in August 2026 were for advertising liable to be mistaken for medicine.

Does export growth explain the rising refusal count?

Partly, and only the part that does not matter.

Korean cosmetics exports to the United States ran to USD 1.45 billion in the first half of 2026, up 41.5% year on year. That growth explains why the refusal count is rising: more shipments produce more refusals.

It does not explain why two-thirds of them are about a sentence. Volume explains the numerator, not the ratio.

What should a Korean brand do before it exports?

Treat the claim as the export document.

Korea's cosmetics industry is organising itself around a set of future deadlines — the mandatory per-product safety assessment phased in from 2028, Illinois' ban on 24 intentionally added substances from July 2028, the EU's packaging rules. All real, and all about what is in the product or what it is wrapped in.

The enforcement actually happening, on both sides of the Pacific, in the month just ended, is about the words on the box.

So: not the safety assessment, not the CPNP dossier, not the certificate of analysis. The sentence — which is currently generated in a marketing process, signed off by nobody in particular, and discovered at a border. Put it under regulatory control before it goes into a deck.